DUBLIN, July 20, 2017 /PRNewswire/ --
The "Global Alzheimer's Drugs Market 2017-2021" report has been added to Research and Markets' offering.
The global alzheimer's drugs market to grow at a CAGR of 1.90% during the period 2017-2021.
The report, Global Alzheimer's Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.
One trend in the market is reformulation of marketed drugs. The global Alzheimer's drugs market is currently witnessing an increasing trend of reformulation of already market drugs to increase patient adherence to the treatment. Drug delivery systems such as transdermal patches, ER formulations, and orally disintegrating tablets increase the efficacy of drugs either by increasing the patient compliance or by increasing the bioavailability of a drug.
According to the report, one driver in the market is appropriate strategies designed to increase public awareness. Although the risk of developing Alzheimer's disease increases exponentially with age, the CDC estimates that approximately 220,000-640,000 Americans under the age of 65 years are suffering from dementia, particularly Alzheimer's disease. The early onset of symptoms of Alzheimer's disease is often called as younger-onset. However, the diagnosis of individuals with younger-onset is delayed by several months or years as these symptoms are often attributed to external factors such as head injury, improper sleep, trauma or tragedy that had occurred in the past, stress conditions, and improper diagnosis of disease.
Further, the report states that one challenge in the market is social stigma associated with Alzheimer's disease. Alzheimer's disease is perceived in different ways in different parts of the world, ranging from a component of aging to a supernatural event. This, in turn, has a negative impact on those suffering from dementia as they often refrain from reporting their symptoms to healthcare providers, leading to low diagnostic rates, thus hampering the market growth. In some parts of the world, public disclosure of such symptoms triggers negative reactions from family and friends leading to quarantine in some cases.
- Eisai Pharmaceuticals
- Johnson & Johnson
Other prominent vendors
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Alzheimer's disease: An overview
PART 06: Market landscape
PART 07: Pipeline landscape
PART 08: Market segmentation by MoA
PART 09: Market assessment of FDA-approved drugs
PART 10: Geographical segmentation
PART 11: Decision framework
PART 12: Drivers and challenges
PART 13: Market trends
PART 14: Vendor landscape
PART 15: Key vendor analysis
PART 16: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/7kkdsg/global
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets